User:Mr. Ibrahem/Lusutrombopag
From Wikipedia, the free encyclopedia
Lusutrombopag, sold under the brand name Mulpleta among others, is a medication used to treat low platelets due to chronic liver disease.[2] It is used before surgery.[1] It is taken by mouth.[1]
Quick Facts Clinical data, Pronunciation ...
Clinical data | |
---|---|
Pronunciation | loo" soo trom' boe pag |
Trade names | Mulpleta, Mulpleo, Lusutrombopag Shionogi, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618043 |
License data |
|
Routes of administration | By mouth |
Drug class | Thrombopoietin receptor agonist[1] |
Legal status | |
Legal status |
|
Identifiers | |
| |
Chemical and physical data | |
Formula | C29H32Cl2N2O5S |
Molar mass | 591.54 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) |
Close
Common side effects include headache.[2] Other side effects may include nausea, portal vein thrombosis, and rash.[3] It is a thrombopoietin receptor agonist which increases platelet numbers.[1][3]
Lusutrombopag was approved in the United States in 2018 and Europe in 2019.[2][3] In the United Kingdom a course of treatment costs the NHS about £800.[1] In the United States this amount costs about 8,900 USD.[4]